NCT03230565 Continuous Infusions vs Scheduled Bolus Infusions
| NCT ID | NCT03230565 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Stanford University |
| Condition | Surgical Procedure, Unspecified |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2018-06-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 240 participants in total. It began in 2018-06-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the study is to compare continuous infusions and scheduled bolus infusions for peripheral nerve blocks and their effect on post-surgical pain.
Eligibility Criteria
Inclusion Criteria: * Adult patients presenting for nerve block catheters for post-operative analgesia * ASA physical status I, II, or III. Exclusion Criteria: * Pregnancy * Incarceration * Age \<18 * BMI \>35 * Pre-operative opioid use \>30 mg morphine equivalents per day * Inability to communicate with investigators by telephone * Pre-existing neuropathy of the operative extremity.
Contact & Investigator
Jean Louis-Horn, MD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT03230565 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Surgical Procedure, Unspecified. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03230565 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT03230565 currently recruiting?
Yes, NCT03230565 is actively recruiting participants. Contact the research team at adeng1@stanford.edu for enrollment information.
Where is the NCT03230565 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT03230565 clinical trial?
NCT03230565 is sponsored by Stanford University. The principal investigator is Jean Louis-Horn, MD at Stanford University. The trial plans to enroll 240 participants.